Metformin as Adjuvant Therapy in Ovarian and Endometrial Cancers

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-319-63483-8_16
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Metformin induces degradation of cyclin D1 via AMPK/GSK3β axis in ovarian cancer

  2017cited by this paper
• Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer.

  2016cited by this paper
• Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.

  2016cited by this paper
• Phase II study of everolimus, letrozole, and metformin in women with advanced/recurrent endometrial cancer.

  2016cited by this paper
• Increased efficacy of metformin corresponds to differential metabolic effects in ovarian tumors in obese versus lean mice

  2016cited by this paper
• Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers

  2016cited by this paper
• Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma

  2016cited by this paper
• Cation‐selective transporters are critical to the AMPK‐mediated antiproliferative effects of metformin in human breast cancer cells

  2016cited by this paper
• NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo

  2016cited by this paper
• Evaluation of resource utilization using time-derived, activity-based costing (TDABC) to result in more effective processes and cost reduction.

  2016cited by this paper
• Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway

  2016cited by this paper
• Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis.

  2016cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• Measuring the biological effect of presurgical metformin treatment in endometrial cancer

  2016cited by this paper
• Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.

  2016cited by this paper
• Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas

  2015cited by this paper
• A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer.

  2015cited by this paper
• Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells.

  2015cited by this paper
• Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.

  2015cited by this paper
• The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells

  2015cited by this paper
• Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer

  2015cited by this paper
• Metformin in cancer treatment and prevention.

  2015cited by this paper
• Supplemental Figure 1

  2014cited by this paper
• Metformin is associated with improved survival in endometrial cancer.

  2014cited by this paper
• Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer

  2014cited by this paper
• The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance.

  2014cited by this paper
• Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

  2014cited by this paper
• Obesity increases tumor aggressiveness in a genetically engineered mouse model of serous ovarian cancer.

  2014cited by this paper
• Effects of metformin on endometrial cancer cell growth in vivo: A preoperative prospective trial

  2014cited by this paper
• CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity.

  2014cited by this paper
• Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.

  2014cited by this paper
• Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK

  2014cited by this paper
• A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer

  2014cited by this paper
• Metformin and the risk of endometrial cancer: a population-based cohort study.

  2014cited by this paper
• Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.

  2014cited by this paper
• Metformin—mode of action and clinical implications for diabetes and cancer

  2014cited by this paper
• Abstract number 11: Metformin had increased efficacy under obese conditions in a novel genetically engineered mouse model of serous ovarian cancer

  2014cited by this paper
• Metformin use and endometrial cancer survival.

  2014cited by this paper
• Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients.

  2013cited by this paper
• Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects.

  2013cited by this paper
• Type I and II endometrial cancers: have they different risk factors?

  2013cited by this paper
• An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice

  2013cited by this paper
• Metformin, at Concentrations Corresponding to the Treatment of Diabetes, Potentiates the Cytotoxic Effects of Carboplatin in Cultures of Ovarian Cancer Cells

  2013cited by this paper
• Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects

  2013cited by this paper
• Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent Manners

  2013cited by this paper
• Low Concentrations of Metformin Selectively Inhibit CD133+ Cell Proliferation in Pancreatic Cancer and Have Anticancer Action

  2013cited by this paper
• Phase 0 study: Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer

  2013cited by this paper
• Repositioning metformin for cancer prevention and treatment.

  2013cited by this paper
• Metformin and the risk of endometrial cancer: a case-control analysis.

  2013cited by this paper
• Chemopreventive effects of metformin on obesity-associated endometrial proliferation.

  2013cited by this paper
• Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy

  2013cited by this paper
• LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.

  2013cited by this paper
• Trials and Tribulations of Interrogating Biomarkers to Define Efficacy of Cancer Risk Reductive Interventions

  2013cited by this paper
• Integrated genomic characterization of endometrial carcinoma

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

  2012cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• LY294002 and Metformin Cooperatively Enhance the Inhibition of Growth and the Induction of Apoptosis of Ovarian Cancer Cells

  2012cited by this paper
• Investigating metformin for cancer prevention and treatment: the end of the beginning.

  2012cited by this paper
• Metformin targets ovarian cancer stem cells in vitro and in vivo.

  2012cited by this paper
• Mortality After Incident Cancer in People With and Without Type 2 Diabetes

  2012cited by this paper
• Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity

  2012cited by this paper
• Metformin inhibits the development and metastasis of ovarian cancer.

  2012cited by this paper
• Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression

  2012cited by this paper
• Metformin: A Potential Novel Endometrial Cancer Therapy

  2012cited by this paper
• Phenformin as prophylaxis and therapy in breast cancer xenografts

  2012cited by this paper
• Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotoxic to ovarian cancer cultures

  2012cited by this paper
• Obesity and Ovarian Cancer Survival: A Systematic Review and Meta-analysis

  2012cited by this paper
• Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway.

  2012cited by this paper
• A phase I study of temsirolimus and metformin in advanced solid tumours

  2012cited by this paper
• Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

  2012cited by this paper
• A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy

  2012cited by this paper
• Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.

  2012cited by this paper
• Metformin intake is associated with better survival in ovarian cancer

  2012cited by this paper
• Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

  2012cited by this paper
• Cardiovascular disease is the leading cause of death among endometrial cancer patients.

  2012cited by this paper
• Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins.

  2011cited by this paper
• Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

  2011cited by this paper
• Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy.

  2011cited by this paper
• Effect of Low-Fat Diets on Plasma Levels of NF-κB–Regulated Inflammatory Cytokines and Angiogenic Factors in Men with Prostate Cancer

  2011cited by this paper
• Effect of Obesity on Survival of Women With Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis of Observational Studies

  2011cited by this paper
• Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.

  2011cited by this paper
• Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells.

  2011cited by this paper
• Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial

  2011cited by this paper
• High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.

  2011cited by this paper
• Understanding obesity and endometrial cancer risk: opportunities for prevention.

  2011cited by this paper
• OCT2 and MATE1 provide bidirectional agmatine transport.

  2011cited by this paper
• Emerging therapeutic targets in endometrial cancer

  2011cited by this paper
• DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma

  2011cited by this paper
• Relevance of the OCT1 transporter to the antineoplastic effect of biguanides.

  2011cited by this paper
• Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

  2011cited by this paper
• Use of metformin and the risk of ovarian cancer: a case-control analysis.

  2011cited by this paper
• Clinical Pharmacokinetics of Metformin

  2011cited by this paper
• Addition of 2-deoxyglucose enhances growth inhibition but reverses acidification in colon cancer cells treated with phenformin.

  2011cited by this paper
• Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.

  2010cited by this paper
• Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial

  2010cited by this paper
• Metformin: A Therapeutic Opportunity in Breast Cancer

  2010cited by this paper
• Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy

  2010cited by this paper
• Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis

  2010cited by this paper
• Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients.

  2010cited by this paper

• No citing papers are available for this paper.